Enzypep
Year of investment: 2014
Enzypep developed a breakthrough technology for the synthesis of peptides using enzymes. The Enzypep technology is expected to become the state-of-the-art in design and preparation of complex peptides. Compared with standard synthesis it results in pharmaceutical products with a much higher purity, at a much lower cost and in a sustainable, environmentally-friendly manner.
QC Polymers
Year of investment: 2014
QC Polymers operates a polymer recycling plant with a nameplate capacity of 50,000 tons/year in Sittard-Geleen to produce polyethylene and polypropylene compounds from post-consumer and post-industrial waste. Typical applications are bottles, crates, pipes and automotive parts.
BioActor
Year of investment: 2012
BioActor develops and markets proprietary health ingredients for use in functional foods, medical nutrition and dietary supplements.
BioActor focuses on the development of proprietary bioactives with human clinical evidence that address health concerns related to metabolic syndrome and ageing such as diabetes, osteoporosis and cardiovascular disease.
For more information on the company and product(s), please refer to the following video:
Q Chip
Year of investment: 2011
Q Chip, based in Cardiff (Wales, UK) commercializes innovative sustained-release drug formulations of injectable therapeutics. The sustained- release can be tailored and administration of the therapeutics is improved. The company was acquired by Midatech Pharma plc in late 2014.
Ekompany Agro
Year of investment: 2011
Ekompany Agro is a manufacturer of controlled release fertilizers using a proprietary and patented process. The company operates a 60,000 ton/year name plate capacity coated fertilizer plant and integrated 150,000 ton blending plant in Born (Netherlands). The assets were acquired by Shandong Kingenta Ecological Engineering early 2016.
TiGenix
Year of investment: 2009
TiGenix is a late-stage regenerative medicine company active in tissue engineering (cartilage repair) and allogeneic cell therapy. It has a marketing agreement with Sobi AB for its ChrondroCelect product in Europe. Its cell therapy products are in advanced stages of clinical trials. TiGenix NV is listed at Euronext Brussels.
Magnamedics
Year of investment: 2008
MagnaMedics engineers and produces magnetic nano- and microparticles that are used in medical devices, drug delivery tools and diagnostic kits. Diagnostic kits are used for determination of biomarkers in body fluids; the company focuses on proteomics and more specifically on high-quantity isolation of proteins as well as on research customers active in high-throughput screening of biomarkers. In 2014 the shares of Limburg Ventures were sold to the other shareholders.
Isobionics
Year of investment: 2008
Isobionics is a company that uses a proprietary biotechnology process for the production of flavor and fragrance ingredients. Its focus is on isoprenoid-based products for food, beverage, flavor and fragrance markets. The biotechnology process delivers products with higher quality and purity, at lower production cost.
Chemtrix
Year of investment: 2008
Chemtrix BV supplies complete and customized microreactor systems for R&D and commercial manufacturing. Chemtrix’ microreactors enhance process efficiency, energy efficiency and safety of chemical synthesis in the fine chemical and pharmaceutical industries.